|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Bristol-Myers Squibb |
| Information provided by: | Bristol-Myers Squibb |
| ClinicalTrials.gov Identifier: | NCT00035152 |
Purpose
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma.
This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly.
The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.
| Condition | Intervention | Phase |
|
Carcinoma, Non-Small-Cell Lung |
Drug: Paclitaxel and carboplatin |
Phase III |
| MedlinePlus related topics: | Cancer Lung Cancer |
| ChemIDplus related topics: | Carboplatin Paclitaxel |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study |
| Official Title: | A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol. |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion Criteria:
Contacts and Locations![]() |
Show 56 Study Locations |
| Bristol-Myers Squibb |
More Information
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm 
  |
| Study ID Numbers: | BMS TAX/MEN.12 |
| First Received: | May 2, 2002 |
| Last Updated: | June 27, 2008 |
| ClinicalTrials.gov Identifier: | NCT00035152 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|